Why Moderna shares surged 27% in June

Growing concern over the emerging delta variant and more long-term supply agreements boosted the stock last month.

| More on:
woman preparing Moderna vaccine

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

What happened

Shares of Moderna (NASDAQ: MRNA) rose 27% in June, according to data from S&P Global Market Intelligence. Known for its highly effective COVID-19 mRNA vaccine, Moderna rose in tandem with the spread of the concerning delta variant across the world in June. The company also announced studies showing its vaccine was highly effective against that variant and others, and it locked up more supply agreements with the U.S. and other countries.

So what

Early in the month, Moderna secured a long-term supply agreement with UNICEF to sell the organization 34 million doses in the fourth quarter of 2021, along with up to 466 million doses in 2022. That was followed up by a purchase of 200 million doses, securing supply into the first quarter 2022, and then another 150 million doses purchased by the European Union, bringing its order commitment total to 460 million, including boosters for new variants in 2022. The new purchase orders by major countries coincided with Moderna's release of clinical data showing its COVID vaccine as protective against six of the newer variants, including the delta variant causing so much concern. Rival Johnson & Johnson's (NYSE: JNJ) vaccine has only shown to be about 60% effective against the delta variant, a lower rate than two-dose vaccines like Moderna's.

Now what

Even after its June run, Moderna's stock trades at a bargain valuation of less than 10 times next year's earnings estimates. That's because investors see the company's huge COVID windfall as a one-time occurrence, and that those earnings will decline in 2023 and beyond. But with the delta variant causing worries -- and with Moderna's vaccine perhaps providing superior protection versus the one-dose Johnson & Johnson -- investors now might be forecasting a longer life for Moderna's COVID franchise than it had previously. Moderna also still isn't given much credit for its fairly large pipeline of other mRNA indications, since mRNA is only a newly commercialized technology. So despite the stock's monster run over the past year, any new COVID variants or new mRNA indications from its pipeline could extend the rally even further.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Should you invest $1,000 in Nvidia right now?

Before you buy Nvidia shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Nvidia wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Billy Duberstein has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Johnson & Johnson and Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

Business woman with her arms folded stands in front of multiple screens.
International Stock News

How did the Magnificent 7 fare this reporting season?

Let's explore the highlights.

Read more »

A man looking at his laptop and thinking.
International Stock News

Amazon: A good quarter but some concerns

Here's our initial take on Amazon's financial report.

Read more »

Man looks up at apple on his head.
International Stock News

Apple: Growth in a difficult environment

Here's our initial take on Apple's financial report.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

Why Microsoft stock popped this week

Microsoft stock was up by 9.5% this week.

Read more »

Electric vehicle such as Tesla being charged at charging station.
International Stock News

Tesla searches for Musk successor: Why this matters

Could Elon get the chainsaw from his own board?

Read more »

customers inside and outside a Microsoft retail store
International Stock News

Microsoft shares earnings report: What's the verdict?

Investors moved the Microsoft share price significantly.

Read more »

Warren Buffett
International Stock News

Countdown to Berkshire's AGM: What do investors expect to hear from Warren Buffett this year?

All eyes will be on Omaha, Nebraska this weekend.

Read more »

A smiling woman holds a Facebook like sign above her head.
International Stock News

Meta surges on blockbuster earnings report

It's a good day to be a Meta investor.

Read more »